Skip to main content
AAO-HNSF 2024 Annual Meeting & OTO EXPO Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Panel Presentations

Rhinology/Allergy

Clinical Practice Guideline: Immunotherapy for Inhalant Allergy

Saturday, September 28, 2024
1:00 PM – 2:00 PM EDT
Location: MBCC, Art Deco 229AB
CME/MOC Credit: 1
Disclosure(s):
Richard K. Gurgel, MD, MSCI:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Fuad M. Baroody, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

James W. Mims, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Stacey L. Ishman, MD, MPH, FACS, FAAP, HCQM:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Cecelia C. Damask, DO:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: The purpose of this clinical practice guideline is to identify quality improvement opportunities and provide clinicians trustworthy, evidence-based recommendations regarding the management of inhaled allergies with immunotherapy. Specific goals of the guideline are to optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce risk of harm.

Allergen immunotherapy is the therapeutic exposure to an allergen or allergens selected by clinical assessment and allergy testing to decrease allergic symptoms and induce immunologic tolerance. Inhalant allergen immunotherapy (AIT) is administered to millions of patients for allergic rhinitis (AR) and allergic asthma (AA) and is most commonly delivered as subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). Despite its widespread use, there is variability in the initiation and delivery of safe and effective immunotherapy, and there are opportunities for evidence-based recommendations for improved patient care.

The target patients for the guideline are any individuals aged 5 years and older with allergic rhinitis, with or without allergic asthma, who are either candidates for immunotherapy or treated with immunotherapy for their inhalant allergies. The target audience is all clinicians involved in the administration of immunotherapy.

Learning Objectives:

  1. Provide clinicians trustworthy, evidence-based recommendations and identify quality improvement opportunities regarding the management of inhaled allergies with immunotherapy.
  2. Optimize patient care, promote safe and effective therapy, reduce unjustified variations in care, and reduce risk of harm.
  3. Empower clinicians to educate patients and their families about allergen immunotherapy and to engage them in shared decision-making.

    Panelist(s)

  • Richard K. Gurgel, MD, MSCI

    Professor
    University of Utah
    Salt Lake City, Utah, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • Fuad M. Baroody, MD

    Director of Pediatric Otolaryngology
    University of Chicago Medicine
    Chicago, IL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • James W. Mims, MD

    Professor
    Wake Forest School of Medicine
    Winston Salem, NC, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • Stacey L. Ishman, MD, MPH, FACS, FAAP, HCQM

    Adjunct Clinical Professor - Otolaryngology Head & Neck Surgery - University of Cincinnati
    Instructor, University of Wisconsin - Madison
    Cincinnati, OH, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

  • CD

    Cecelia C. Damask, DO

    DO
    Orlando ENT and Allergy
    Orlando, FL, United States

    Disclosure(s):

    faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.